Abstract: Objective To assess the efficacy and safety of Ustekinumab for plaque psoriasis with meta-analysis. Method Both foreign and Chinese databases were searched to identity randomized controlled trials（RCTs） that reported the efficacy and safety of Ustekinumab for plaque psoriasis. We also searched the references of all primary studies. Two reviewers assessed the quality of each trial and extracted data independently. The Cochrane Collaboration’s RevMan 4.2.2 software was used for statistical analysis. Results A total of 4 RCTs were included, including 2 437 patients. Meta-analysis results suggested that Ustekinumab was superior to placebo for moderate to severe plaque psoriasis at week 12,but there was no significant difference between the two groups of Ustekinumab at week 12（RR=0.94,95%CI 0.82~1.07, P=0.34）; at week 28, the Ustekinumab 90 mg group was superior to the Ustekinumab 45 mg group in the skin lesions subsidence（RR=0.89, 95%CI 0.84~0.95, P=0.000 6）, but there was no significant difference in the improvement of the life quality（RR=0.93, 95%CI 0.85~1.01, P=0.08）. The most common adverse events were upper respiratory tract infection, nasopharyngitis, headache, there were no significant differences between Ustekinumab and placebo, the two groups of Ustekinumab had no significant differences too. Conclusion The present study shows Ustekinumab to be safe and effective for patients with moderate-severe plaque psoriasis.